Compare · ABT and JNJ
Abbott vs. Johnson & Johnson
Revenue, growth, margins, cash flow and cash returned, side by side from each company's latest annual report.
Both sell medical devices. Abbott also sells diagnostic tests, nutrition products and branded generic medicines; Johnson & Johnson pairs its MedTech business with Innovative Medicine, which sells prescription drugs. Below are the figures each one reported in its latest annual report (Form 10-K), side by side, with links to the filing behind every number. Both fiscal years end in December, so the periods line up. Why fiscal years differ.
Comparing Abbott fiscal 2025 (ended Dec 31, 2025) with Johnson & Johnson fiscal 2025 (ended Dec 28, 2025)
AbbottJohnson & Johnson
Each pair of bars shows both companies on one scale.
Revenue and growth
| Company | Prior year | Latest year | Change |
|---|---|---|---|
| Abbott (FY2024 to FY2025) | $42.0B | $44.3B | +5.7% |
| Johnson & Johnson (FY2024 to FY2025) | $88.8B | $94.2B | +6.0% |
Abbott reports net sales: sales of medical devices, diagnostic tests, nutrition products and branded generic medicines. Johnson & Johnson reports sales to customers: sales of medicines and medical devices, net of rebates, returns and discounts.
Margins
| Company | Revenue | Net income | Net margin |
|---|---|---|---|
| Abbott FY2025 | $44.3B | $6.5B | 14.7% |
| Johnson & Johnson FY2025 | $94.2B | $26.8B | 28.5% |
Operating income is shown only when both companies report it as a line in their income statement.
Margin is the profit line divided by revenue, worked out by Ticker Sage from the linked figures. What profit margins measure.
Cash flow and cash returned
| Company | Cash from operations | Capital spending | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|
| Abbott FY2025 | $9.6B | $2.2B | $7.4B | $893M | $4.1B |
| Johnson & Johnson FY2025 | $24.5B | $4.8B | $19.7B | $6.0B | $12.4B |
Capital spending is property and equipment for both companies, as each company labels it in the cash flow statement. Free cash flow isn't a GAAP line; Ticker Sage works it out the same way for both. How free cash flow works · How buybacks work · How dividends work.
How each one makes money
Abbott
Medical Devices, its largest segment, includes FreeStyle Libre glucose monitors, heart devices and neuromodulation products. Diagnostics sells lab, point-of-care and rapid tests. Nutrition sells infant and adult nutrition products. Established Pharmaceuticals sells branded generic medicines in emerging markets.
Its fiscal year is the calendar year.
Johnson & Johnson
Innovative Medicine sells prescription drugs in oncology (such as Darzalex), immunology (Stelara, Tremfya), neuroscience, pulmonary hypertension, cardiovascular and infectious diseases. MedTech sells surgical tools, orthopaedic implants, heart devices such as electrophysiology catheters, and contact lenses and other vision products.
J&J has said it plans to separate its Orthopaedics business. Its fiscal year ends on the Sunday closest to the end of December.
Main risks each one lists
Abbott
- Each business faces strong competitors and new technology.
- Governments and insurers push down prices for devices, tests and medicines.
- Product problems can lead to recalls, lawsuits and lost sales.
- Products need approvals from the FDA and regulators abroad.
- Much of its sales are outside the US, so currencies and local conditions matter.
Johnson & Johnson
- Generics, biosimilars and new rivals can take sales when patents expire or are challenged.
- Product liability cases, including talc lawsuits, and other legal matters could lead to large payments.
- Healthcare reform, drug price negotiation and stricter regulation could lower prices or delay products.
- Plant problems, supplier failures or counterfeit products could interrupt supply.
- Research may not produce new products on time.
How they differ
- Size. Johnson & Johnson reported $94.2B of revenue for fiscal 2025, and Abbott $44.3B for fiscal 2025.
- Growth. Abbott's revenue grew 5.7% in its latest year and Johnson & Johnson's 6.0%.
- Margins. Johnson & Johnson kept 28.5% of revenue as net income and Abbott 14.7%.
- Devices. Abbott's largest segment, Medical Devices, includes FreeStyle Libre glucose monitors. J&J MedTech sells surgical tools, orthopaedic implants, heart devices and vision products.
- Planned change. J&J has said it plans to separate its orthopaedics business.
- Where the money goes. In the latest year Johnson & Johnson spent $6.0B on buybacks and $12.4B on dividends, and Abbott $893M and $4.1B.
Differences in size, growth or margin describe the past year only. None of this says which business will do better.
Sources
- Abbott Form 10-K for fiscal 2025, filed Feb 20, 2026
- Johnson & Johnson Form 10-K for fiscal 2025, filed Feb 11, 2026
Abbott company file → · Johnson & Johnson company file →
Common questions
Which is bigger by revenue, Johnson & Johnson or Abbott?
Johnson & Johnson reported $94.2B of revenue for fiscal 2025 and Abbott $44.3B for fiscal 2025.
Does Abbott sell prescription drugs?
Only branded generic medicines in emerging markets, through its Established Pharmaceuticals segment.
How do their profit margins compare?
In the latest fiscal year Johnson & Johnson's net margin was 28.5% and Abbott's was 14.7%, worked out from the net income and revenue in each 10-K.
Where do these numbers come from?
From each company's latest Form 10-K filed with the SEC. Every figure on this page links to the filing it came from.
Disclosures
- Editor holdings
- The editor holds no position in any company named on this page. As of Oct 25, 2026.
- Compensation
- Nobody paid for this page. No affiliate links on this page.
- Sources
- Each company's own SEC filings, linked next to each number.
- Last updated
- Oct 26, 2026
General education, the same for every reader. Not a recommendation to buy, sell or hold any security, and it doesn't consider your situation.
More in Learn · Methodology & Disclosures explains where every number comes from.